Prudential Financial Inc. bought a new position in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 20,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $138,000. Prudential Financial Inc. owned approximately 0.13% of Cumberland Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of CPIX. Stonepine Capital Management LLC grew its position in Cumberland Pharmaceuticals by 2.7% during the fourth quarter. Stonepine Capital Management LLC now owns 1,306,911 shares of the specialty pharmaceutical company’s stock worth $9,619,000 after buying an additional 34,720 shares in the last quarter. Renaissance Technologies LLC grew its position in Cumberland Pharmaceuticals by 4.5% during the fourth quarter. Renaissance Technologies LLC now owns 330,300 shares of the specialty pharmaceutical company’s stock worth $2,431,000 after buying an additional 14,295 shares in the last quarter. Finally, Ariel Investments LLC grew its position in Cumberland Pharmaceuticals by 2.6% during the fourth quarter. Ariel Investments LLC now owns 910,076 shares of the specialty pharmaceutical company’s stock worth $6,698,000 after buying an additional 22,932 shares in the last quarter. Institutional investors and hedge funds own 34.53% of the company’s stock.
Cumberland Pharmaceuticals stock opened at $6.00 on Tuesday. Cumberland Pharmaceuticals, Inc. has a 52 week low of $5.53 and a 52 week high of $7.96. The company has a current ratio of 4.10, a quick ratio of 3.70 and a debt-to-equity ratio of 0.20.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 4.37% and a negative net margin of 22.65%. The firm had revenue of $8.59 million during the quarter, compared to analysts’ expectations of $9.71 million. research analysts forecast that Cumberland Pharmaceuticals, Inc. will post -0.24 EPS for the current year.
Several research firms recently commented on CPIX. ValuEngine upgraded Cumberland Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. B. Riley began coverage on Cumberland Pharmaceuticals in a research report on Tuesday, April 17th. They set a “buy” rating and a $9.25 target price for the company.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.